

Does the presence of a hiatal hernia affects the efficacy of the reflux inhibitor baclofen?

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON23260

Source

Nationaal Trial Register

Brief title

N/A

Health condition

Gastroesophageal reflux disease (GERD), hiatal hernia

Sponsors and support

Primary sponsor: Academic Medical Center (AMC), Department of Gastroenterology and Hepatology

Source(s) of monetary or material Support: AstraZeneca R&D, Mölndal, Sweden

Intervention

Outcome measures

Primary outcome

- The number of reflux episodes (acid and non acid) measured over 24 hours

Secondary outcome

- Total acid exposure time, the composition of the refluxate and the proximal extent of the refluxate

Study description

Background summary

The presence of a hiatal hernia may hamper the efficacy of anti-TLESR therapy in the treatment of gastroesophageal reflux disease (GERD) as other mechanisms for reflux to occur become more important. Therefore, a randomized, placebo controlled double blind crossover study will be performed, whereby the effect of baclofen on the rate of reflux episodes will be evaluated in GERD patient with (≥ 3 cm) and without hiatal hernia. Patients will undergo twice a combined ambulatory 24 hours impedance pH metry measurement while on PPI's and 3x20mg baclofen or placebo. Acid and non-acid reflux rate, acid exposure time and acid clearance will be analysed for both study days and compared between both patient groups.

Study objective

The efficacy of reflux inhibitors, which block transient lower esophageal sphincter relaxations (TLESRs), to reduce acid and non-acid exposure may be hampered in the presence of a hiatal hernia, as other mechanisms of reflux become more important.

Study design

The ambulatory impedance/ pH metry will be performed twice, at day 11 after the start of baclofen / placebo and with at least a 7 days wash out period between both study periods.

Intervention

Twice a 24 hours ambulatory combined impedance measurement and pH metry (transnasally).

A dose of 3x20mg baclofen and a dose of 3xplacebo; the initial dose consisted of 3 x 5 mg baclofen. Every fourth day, the dose was increased by 5 mg three times daily until a dose of 20 mg three times daily was reached after 10 days.

Contacts

Public

Academic Medical Center

Meibergdreef 9
H. Beaumont
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5668708

Scientific

Academic Medical Center

Meibergdreef 9
H. Beaumont
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5668708

Eligibility criteria

Inclusion criteria

1. GERD patients (M/F) with typical heartburn symptoms at least 3 times weekly during the last 3 months
2. Daily use of PPIs
3. 18-70 years
4. Hiatal hernia < 3 cm
5. Hiatus hernia > or = 3 cm

Exclusion criteria

1. Thoracal or upper abdominal surgery
2. Use of drugs which influence gastrointestinal motility
3. Systemical illness which influence esophageal motility
4. Epilepsy
5. Renal function disorder
6. Pregnancy

Study design

Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-03-2007
Enrollment:	30
Type:	Actual

Ethics review

Positive opinion	
Date:	10-08-2008
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL1340
NTR-old	NTR1401
Other	: MEC 06/183
ISRCTN	ISRCTN wordt niet meer aangevraagd

Study results

Summary results

N/A